MCID: GNR004
MIFTS: 55

Generalized Anxiety Disorder

Categories: Genetic diseases, Mental diseases

Aliases & Classifications for Generalized Anxiety Disorder

MalaCards integrated aliases for Generalized Anxiety Disorder:

Name: Generalized Anxiety Disorder 12 73 36 54 15 62 17 70 32
Anxiety Generalized 54

Classifications:



External Ids:

Disease Ontology 12 DOID:14320
KEGG 36 H01662
ICD9CM 34 300.02
NCIt 50 C92622
SNOMED-CT 67 192401002
ICD10 32 F41.1
UMLS 70 C0270549

Summaries for Generalized Anxiety Disorder

PubMed Health : 62 About generalized anxiety disorder: Everyone feels frightened or very scared every once in a while. In dangerous situations, for instance on the highway, fear can help to protect you. It puts the body in a state of readiness so that it can react to threats quickly. Worries and anxiety about the future, your job or family might also help to guard against danger. For example, by keeping you from making rash decisions that could lead to difficult situations. But if these sorts of fears become overwhelming, they can be very distressing. Some people end up constantly worrying about practically everything. If fears and anxiety overshadow everything else and don’t go away, the person may have developed generalized anxiety disorder (GAD). People with generalized anxiety disorder usually realize that their fears are exaggerated, but they aren’t able to control them. Although it’s difficult to get out of this state, there are treatments that can help.

MalaCards based summary : Generalized Anxiety Disorder, also known as anxiety generalized, is related to neurotic disorder and depression. An important gene associated with Generalized Anxiety Disorder is HTR1A (5-Hydroxytryptamine Receptor 1A), and among its related pathways/superpathways are Peptide ligand-binding receptors and cAMP signaling pathway. The drugs Lorazepam and Norepinephrine have been mentioned in the context of this disorder. Affiliated tissues include amygdala, cortex and brain, and related phenotypes are Decreased viability and Decreased viability

Disease Ontology : 12 An anxiety disorder that is characterized by long-lasting anxiety that is not focused on any one object or situation.

KEGG : 36 Generalized anxiety disorder is a persistent and common mental disorder. This disorder is twice as common in women than it is in men. The symptoms include generalised and persistent excessive anxiety and a combination of various psychological and somatic complaints, such as threat, restlessness, irritability, sleep disturbance, tension, palpitations, dry mouth, and sweating. The symptoms overlap greatly with those of other mental disorders and we could regard the disorder as part of a spectrum of mood and related disorders rather than an independent disorder. Generalized anxiety disorder has a relapsing course, and intervention rarely results in complete resolution of symptoms. But in the short term and medium term, effective treatments include psychological therapies, such as cognitive behavioural therapy, and pharmacological treatments, mainly selective serotonin reuptake inhibitors (SSRIs).

Wikipedia : 73 Generalized anxiety disorder (GAD) is an anxiety disorder characterized by excessive, uncontrollable and... more...

Related Diseases for Generalized Anxiety Disorder

Diseases related to Generalized Anxiety Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 256)
# Related Disease Score Top Affiliating Genes
1 neurotic disorder 31.8 SLC6A4 MAOA HTR2A HTR1A COMT BDNF
2 depression 31.5 TPH1 SLC6A4 NR3C1 MAOA HTR3A HTR2A
3 somatization disorder 31.0 SLC6A4 HTR1A COMT
4 sexual disorder 30.9 SLC6A4 HTR2A HTR1A CYP2D6 BDNF
5 social phobia 30.7 SLC6A4 MAOA HTR3A HTR2A HTR1A DRD2
6 obsessive-compulsive personality disorder 30.6 SLC6A4 HTR2A COMT
7 acute stress disorder 30.5 SLC6A4 NR3C1 HTR1A CRP CRHR1 BDNF
8 hypochondriasis 30.5 SLC6A4 HTR2A HTR1A CRHR1 BDNF
9 agoraphobia 30.5 SLC6A4 SLC6A2 RGS2 NPSR1 MAOA HTR2A
10 withdrawal disorder 30.5 TSPO SLC6A3 NPY HTR1A CRHR1
11 postpartum depression 30.5 SLC6A4 NR3C1 MAOA HTR1A COMT BDNF
12 separation anxiety disorder 30.4 TSPO SLC6A4 SLC6A3 MAOA HTR1A COMT
13 alexithymia 30.4 SLC6A4 HTR1A DRD2 CRP COMT
14 dysthymic disorder 30.4 SLC6A4 SLC6A3 SLC6A2 MAOA HTR2A HTR1A
15 conversion disorder 30.4 HTR2A COMT BDNF
16 post-traumatic stress disorder 30.3 SLC6A4 NR3C1 MAOA HTR2A DRD2 CRP
17 phobia, specific 30.2 SLC6A4 RGS2 MAOA HTR2A HTR1A CRHR1
18 antisocial personality disorder 30.2 SLC6A4 SLC6A3 MAOA HTR2A DRD2 COMT
19 adjustment disorder 30.2 TSPO SLC6A4 NPY HTR2A HTR1A CYP2D6
20 bruxism 30.2 SLC6A4 HTR2A HTR1A DRD2 COMT
21 constipation 30.2 SLC6A4 SLC6A2 NPY HTR3A CYP2D6 CRP
22 tic disorder 30.1 SLC6A4 SLC6A3 MAOA HTR2A DRD2 COMT
23 alcohol use disorder 30.1 SLC6A4 SLC6A3 HTR3A HTR2A HTR1A DRD2
24 bipolar i disorder 30.1 SLC6A4 HTR2A HTR1A DRD2 COMT BDNF
25 eating disorder 30.1 SLC6A4 SLC6A3 NPY HTR2A DRD2 COMT
26 mental depression 30.1 TPH1 SLC6A4 SLC6A3 SLC6A2 NR3C1 MAOA
27 neuroleptic malignant syndrome 30.1 HTR2A HTR1A DRD2 CYP2D6
28 irritable bowel syndrome 30.0 TPH1 SLC6A4 HTR3A HTR2A HTR1A CRP
29 melancholia 29.9 SLC6A4 MAOA HTR2A HTR1A CRP BDNF
30 serotonin syndrome 29.9 SLC6A4 MAOA HTR3A HTR2A HTR1A CYP2D6
31 phobic disorder 29.8 SLC6A4 SLC6A3 RGS2 MAOA HTR2A HTR1A
32 personality disorder 29.8 TPH1 SLC6A4 SLC6A3 NR3C1 MAOA HTR3A
33 fibromyalgia 29.8 TSPO SLC6A4 NPY HTR3A HTR2A CRP
34 anorexia nervosa 29.8 SLC6A4 SLC6A2 NPY MAOA HTR2A HTR1A
35 tobacco addiction 29.8 TPH1 SLC6A4 SLC6A3 MAOA HTR2A DRD2
36 dementia 29.8 TSPO SLC6A3 HTR2A DRD2 COMT BDNF
37 chronic fatigue syndrome 29.8 SLC6A4 NR3C1 MAOA HTR2A HTR1A CRHR1
38 oppositional defiant disorder 29.8 SLC6A4 SLC6A3 SLC6A2 MAOA HTR2A DRD2
39 obsessive-compulsive disorder 29.7 TPH1 SLC6A4 SLC6A3 NPY NPSR1 MAOA
40 movement disease 29.7 SLC6A3 HTR1A DRD2 CYP2D6 COMT BDNF
41 anxiety 29.7 TSPO TPH1 SLC6A4 SLC6A3 SLC6A2 RGS2
42 panic disorder 29.7 TSPO TPH1 SLC6A4 SLC6A3 SLC6A2 RGS2
43 heart disease 29.6 SLC6A4 NR3C1 NPY HTR2A CYP2D6 CRP
44 mood disorder 29.6 TPH1 SLC6A4 SLC6A3 SLC6A2 NR3C1 NPY
45 substance dependence 29.6 TPH1 SLC6A4 SLC6A3 MAOA DRD2 CYP2D6
46 major depressive disorder 29.6 TPH1 SLC6A4 SLC6A3 SLC6A2 NR3C1 NPY
47 alzheimer disease 29.5 TSPO SLC6A4 HTR2A DRD2 CYP2D6 COMT
48 bulimia nervosa 29.5 SLC6A4 NPY MAOA HTR3A HTR2A DRD2
49 sleep disorder 29.4 SLC6A4 SLC6A3 NPY HTR2A HTR1A CRP
50 substance abuse 29.4 SLC6A4 SLC6A3 NPY MAOA HTR2A HTR1A

Comorbidity relations with Generalized Anxiety Disorder via Phenotypic Disease Network (PDN): (show all 18)


Acute Cystitis Anxiety
Bronchitis Dependent Personality Disorder
Dysthymic Disorder Esophagitis
Histrionic Personality Disorder Hypertension, Essential
Hypochondriasis Hypothyroidism
Irritable Bowel Syndrome Major Depressive Disorder
Obsessive-Compulsive Disorder Obsessive-Compulsive Personality Disorder
Osteoporosis Personality Disorder
Schizophreniform Disorder Somatization Disorder

Graphical network of the top 20 diseases related to Generalized Anxiety Disorder:



Diseases related to Generalized Anxiety Disorder

Symptoms & Phenotypes for Generalized Anxiety Disorder

GenomeRNAi Phenotypes related to Generalized Anxiety Disorder according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00106-A-0 9.84 MAOA NR3C1
2 Decreased viability GR00240-S-1 9.84 COMT
3 Decreased viability GR00249-S 9.84 SLC6A4 COMT CRHR1 PSMD9 SLC6A2 TPH1
4 Decreased viability GR00381-A-1 9.84 HTR1A HTR3A SLC6A4 CYP2D6 RGS2
5 Decreased viability GR00381-A-3 9.84 HTR1A HTR3A SLC6A4
6 Decreased viability GR00386-A-1 9.84 COMT SLC6A2
7 Decreased viability GR00402-S-2 9.84 HTR1A HTR3A CYP2D6 NPY RGS2

MGI Mouse Phenotypes related to Generalized Anxiety Disorder:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.33 BDNF COMT CRHR1 DRD2 HTR1A HTR2A
2 homeostasis/metabolism MP:0005376 10.16 BDNF COMT CRHR1 CRP DRD2 HTR1A
3 cardiovascular system MP:0005385 10.15 COMT CRHR1 CRP DRD2 HTR1A MAOA
4 endocrine/exocrine gland MP:0005379 10.06 BDNF COMT CRHR1 DRD2 HTR2A HTR3A
5 nervous system MP:0003631 9.77 BDNF COMT CRHR1 DRD2 HTR1A HTR3A
6 muscle MP:0005369 9.76 DRD2 HTR2A HTR3A NR3C1 RGS2 SLC6A3
7 normal MP:0002873 9.28 BDNF CRHR1 DRD2 NPY NR3C1 RGS2

Drugs & Therapeutics for Generalized Anxiety Disorder

PubMed Health treatment related to Generalized Anxiety Disorder: 62

There are different ways to gradually get a handle on an anxiety disorder . It is unrealistic to expect a quick and simple “cure,” but you can find better ways to deal with stress and anxiety. Medication may also relieve some of the symptoms. There are different kinds of treatment approaches: Psychological treatments : These include approaches like cognitive behavioral therapy . This therapy can help you to learn how to control and then change your thoughts and fears. Relaxation techniques such as autogenic training and progressive muscle relaxation can help you to relax and handle stress better. These techniques are often part of psychological treatment . Medication: The most commonly used medications for anxiety disorders are antidepressants. Some people also use herbal sedatives such as valerian. Self-help: Self-help groups offer you the opportunity to share your thoughts, feelings and experiences with others who have the same condition. Some people also find it helpful to learn more about the disorder – be it from books, information leaflets or on the Internet. It is hard to get a handle on severe anxiety , but many people succeed over time. A therapist can help to reveal the underlying patterns of the worries and anxiety. With their guidance, it is possible to learn how to control harmful thoughts and behavior patterns so that they no longer dominate your life. It can take a lot of patience to find your way back to a life with less anxiety, but a noticeable improvement can often already be achieved after a few weeks.

Drugs for Generalized Anxiety Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 121)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Lorazepam Approved Phase 4 846-49-1 3958
2
Norepinephrine Approved Phase 4 51-41-2 439260
3
Aripiprazole Approved, Investigational Phase 4 129722-12-9 60795
4
Tiagabine Approved, Investigational Phase 4 115103-54-3 60648
5
Alprazolam Approved, Illicit, Investigational Phase 4 28981-97-7 2118
6
Chamomile Approved, Experimental, Investigational Phase 4
7
Eszopiclone Approved, Investigational Phase 4 138729-47-2 969472
8
Risperidone Approved, Investigational Phase 4 106266-06-2 5073
9
Sertraline Approved Phase 4 79617-96-2 68617
10
Sodium citrate Approved, Investigational Phase 4 68-04-2
11
Valproic acid Approved, Investigational Phase 4 99-66-1 3121
12
Paroxetine Approved, Investigational Phase 4 61869-08-7 43815
13
Vortioxetine Approved, Investigational Phase 4 508233-74-7 9966051
14
Buspirone Approved, Investigational Phase 4 36505-84-7 2477
15
Dopamine Approved Phase 4 62-31-7, 51-61-6 681
16
Ziprasidone Approved Phase 4 146939-27-7 60854
17
Methadone Approved Phase 4 76-99-3 4095
18
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
19 Kava Approved, Investigational, Nutraceutical Phase 4 9000-38-8
20
Black cohosh Experimental Phase 4
21
Tandospirone Investigational Phase 4 87760-53-0
22 Antiemetics Phase 4
23 Hypnotics and Sedatives Phase 4
24 GABA Modulators Phase 4
25 Anticonvulsants Phase 4
26 Analgesics, Opioid Phase 4
27 Serotonin and Noradrenaline Reuptake Inhibitors Phase 4
28 Analgesics Phase 4
29 Duloxetine Hydrochloride Phase 4
30 Venlafaxine Hydrochloride Phase 4
31 Hormones Phase 4
32 Dopamine agonists Phase 4
33 calcium channel blockers Phase 4
34 Calcium, Dietary Phase 4
35 Adrenergic alpha-Agonists Phase 4
36 Vasoconstrictor Agents Phase 4
37 Sympathomimetics Phase 4
38 Citrate Phase 4
39 Desvenlafaxine Succinate Phase 4 386750-22-7
40 Cytochrome P-450 Enzyme Inhibitors Phase 4
41 Serotonin Uptake Inhibitors Phase 4
42 Serotonin 5-HT1 Receptor Agonists Phase 4
43 Serotonin 5-HT3 Receptor Antagonists Phase 4
44 Serotonin Receptor Agonists Phase 4
45 Neurotransmitter Agents Phase 4
46 Psychotropic Drugs Phase 4
47 Antidepressive Agents Phase 4
48 Quetiapine Fumarate Phase 4 111974-72-2
49 Antipsychotic Agents Phase 4
50 Dopamine Agents Phase 4

Interventional clinical trials:

(show top 50) (show all 238)
# Name Status NCT ID Phase Drugs
1 Combination of Paroxetine CR and Quetiapine for the Treatment of Refractory Generalized Anxiety Disorder Completed NCT00113295 Phase 4 Continued Paroxetine CR;Quetiapine;Placebo
2 Effect of Duloxetine on Opioid Use After Total Knee Arthroplasty: A Double-blinded Randomized Control Trial Completed NCT03271151 Phase 4 Cymbalta
3 Microtuning a Bonafide Treatment for GAD Patients - A Randomized Controlled Trial. Completed NCT02039193 Phase 4
4 Duloxetine Versus Placebo in the Treatment of Elderly Patients With Generalized Anxiety Disorder Completed NCT01118780 Phase 4 Duloxetine;Placebo
5 Stress Reduction Techniques and Anxiety: Therapeutic and Neuroendocrine Effects Completed NCT01033851 Phase 4
6 Aripiprazole for the Treatment of Refractory Anxiety: Impact on Clinical Outcomes, Resilience and Neuroendocrinologic Parameters Completed NCT00438386 Phase 4 Aripiprazole
7 Black Cohosh Therapy for Menopause-Related Anxiety Completed NCT00120458 Phase 4
8 A Multicenter, Randomized, Open-label, Parallel Design Trial to Compare Time to Response in the Symptoms of Anxiety to Concomitant Treatment With Niravam™ and an SSRI or SNRI to Treatment With an SSRI or SNRI Alone in Subjects With Generalized Anxiety Disorder or Panic Disorder Completed NCT00266409 Phase 4 Niravam;SSRI/SNRI
9 Cognitive-Behavioral Therapy and Pharmacotherapy Augmentation for Generalized Anxiety Disorder: A Pilot Investigation Completed NCT00219349 Phase 4 escitalopram
10 Long Term Safety And Efficacy Study Of Pregabalin (Lyrica) In Subjects With Generalized Anxiety Disorder Completed NCT00624780 Phase 4 Pregabalin;Lorazepam;Pregabalin;Placebo
11 Efficacy and Safety of Escitalopram in Patients With Generalized Anxiety Disorder; Open-label, One Arm Postmarketing Study in Russia Completed NCT00902564 Phase 4 Escitalopram
12 Tandospirone Citrate in the Treatment of Patients With Generalized Anxiety Disorder: a Multi-center, Randomized, Usual Dose-controlled Trial Completed NCT01614041 Phase 4 Usual dose treatment of Tandospirone;Comparative high dose of tandospirone treatment
13 Chamomile Therapy for Generalized Anxiety Disorder Completed NCT00645983 Phase 4
14 Randomized, Double-blind, Placebo-controlled Study of a Benzodiazepine vs Placebo on Functional Magnetic Resonance Imaging (fMRI) of the Brain, and on Behavioral/Clinical Measures in Patients With Generalized Anxiety Disorder Completed NCT00662259 Phase 4 Alprazolam (Xanax);Placebo
15 Pharmacological Treatment of Generalized Anxiety Disorder in the Elderly Completed NCT00701675 Phase 4 sertraline 50 mg daily;sertraline 100 mg daily;Placebo 50 or 100 mg
16 Kava for the Treatment of Generalised Anxiety Disorder: A Double-Blind Randomised Placebo-Controlled Trial Completed NCT02219880 Phase 4
17 Efficacy of Serotonin-Norepinephrine Reuptake Inhibitor (SNRI) Treatment on Prefrontality in Patients With Generalized Anxiety Disorder (GAD) and Other Comorbidities Completed NCT01975480 Phase 4 Desvenlafaxine
18 A Pilot Study of Cranial Electrotherapy Stimulation[CES] for Generalized Anxiety Disorder Completed NCT00539357 Phase 4
19 A 14 Week Open-Label Study to Evaluate the Tolerability of Switching From an SSRI to Tiagabine(GABITRIL) in Order to Alleviate SSRI Induced Sexual Dysfunction in Generalized Anxiety Disorder Patients Completed NCT00174850 Phase 4 Gaitril
20 A Randomized, Double-Blind, Placebo-Controlled Study of Risperidone Monotherapy in Ambulatory Bipolar Disorder With Current at Least Moderately Severe Anxiety and Lifetime Panic Disorder or Generalized Anxiety Disorder Completed NCT00167479 Phase 4 risperidone (Risperdal)
21 Pharmacotherapy of Late-Life Generalized Anxiety Disorder Completed NCT00105586 Phase 4 Escitalopram
22 A Randomized, Double-Blind, Placebo-Controlled Study of Ziprasidone in Bipolar Disorder With Comorbid Lifetime Panic or Generalized Anxiety Disorder Completed NCT01172652 Phase 4 Ziprasidone;Placebo
23 Short-term Versus Long-term Treatment in Generalized Anxiety Disorder Completed NCT00183274 Phase 4 Venlafaxine XR;Placebo
24 An Open Label Trial of Duloxetine in the Treatment of Irritable Bowel Syndrome and Comorbid Generalized Anxiety Disorder Completed NCT00961298 Phase 4 Duloxetine
25 The Efficacy of Eszopiclone 3 mg as Adjunctive Therapy in Subjects With Insomnia Related to Generalized Anxiety Disorder. Completed NCT00235508 Phase 4 Eszopiclone (Lunesta)
26 A Randomized, Double-blind, Placebo-controlled Study of Quetiapine SR and Divalproex Sodium ER on Anxiety in Bipolar Disorder With at Least Moderately Severe Current Anxiety and Lifetime Panic or Generalized Anxiety Disorder. Completed NCT00579280 Phase 4 quetiapine SR;divalproex sodium ER;placebo
27 Enhanced Identification of Very Early Response to Seroquel XR Added to an Antidepressant for the Treatment of Major Depressive Disorder With or Without Generalized Anxiety Disorder Completed NCT00892463 Phase 4 Quetiapine (Seroquel) XR
28 Interventional, Open-label Effectiveness Study of Flexible Doses of Vortioxetine on Depressive Symptoms in Patients With Major Depressive Disorder Comorbid With Generalized Anxiety Disorder Recruiting NCT04220996 Phase 4 Vortioxetine
29 Psycho-biological Substrates of Therapeutic Benefit of Thermal Cure on Generalized Anxiety Disorders (Insula-TOP) Recruiting NCT03277339 Phase 4 Paroxetine
30 Buspirone for the Treatment of Anxiety in Williams Syndrome Not yet recruiting NCT04807517 Phase 4 Buspirone
31 Ziprasidone for the Treatment of Generalized Anxiety Comorbidity in Patients With Bipolar Disorder Terminated NCT00374543 Phase 4 Ziprasidone;Placebo
32 A Prospective, Sixteen-Week, Double-Blind, Placebo-Controlled, Trial of Seroquel in Combination With Treatment as Usual in Patients With GAD and Remitted Comorbid Opiate Dependence Terminated NCT00668265 Phase 4 Quetiapine
33 An Open-label Pilot Study to Examine the Value of Substituting Quetiapine for Benzodiazepines in Treatment-refractory Patients With Unipolar Depression or Generalized Anxiety Disorder and Chronic Benzodiazepine Use Terminated NCT01244711 Phase 4 quetiapine
34 A Double-blind, Randomized, Controlled, Phase III Study of an Herbal Medicine Association for Generalized Anxiety Disorder Unknown status NCT01178632 Phase 3 Passiflora;Valeriana officinalis
35 The Effect of Saffron (Crocus Satious L.) in the Treatment of Mild to Moderate Generalized Anxiety Disorder: a Double Blind Randomized Controlled Trial Unknown status NCT02800733 Phase 2, Phase 3
36 A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Active-Controlled Study of the Efficacy and Safety of Sustained-Release Quetiapine Fumarate (SEROQUEL®) Compared With Placebo in the Treatment of Generalized Anxiety Disorder Completed NCT00329446 Phase 3 Quetiapine Fumarate;Escitalopram oxylate
37 A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study of the Efficacy and Safety of Sustained-Release Quetiapine Fumarate (SEROQUEL®) Compared With Placebo in the Treatment of Generalized Anxiety Disorder Completed NCT00329264 Phase 3 Quetiapine fumarate
38 A Multicenter, Randomized, Double-Blind, Placebo Controlled Trial of Troriluzole in Generalized Anxiety Disorder Completed NCT03829241 Phase 3 Troriluzole;Placebo
39 An 8-Week, Double-Blind, Placebo-Controlled, Phase 3 Trial of Pregabalin (150-600 mg/Day) in the Adjunctive Treatment of Patients With Generalized Anxiety Disorder (GAD) Who Have Not Optimally Responded to Existing Therapies(GAD) Completed NCT00413010 Phase 3 pregabalin;placebo
40 A 10-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Flexible-Dosage Study to Evaluate the Efficacy and Safety of Gabitril(up to 16 mg/Day) in the Treatment of Adults With Generalized Anxiety Disorder Completed NCT00236067 Phase 3 Gabitril
41 A Double-Blind, Placebo-Controlled, Flexible-Dose Study of Vilazodone in Patients With Generalized Anxiety Disorder. Completed NCT01844115 Phase 3 Placebo;Vilazodone
42 A Double-Blind, Placebo-Controlled, Flexible-Dose Study of Vilazadone in Patients With Generalized Anxiety Disorder Completed NCT01766401 Phase 3 Placebo;Vilazadone
43 An International, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Active-Controlled Study of the Efficacy and Safety of Sustained-Release Quetiapine Fumarate (Seroquel SR™ ) in the Treatment of Generalized Anxiety Disorder (SILVER) Completed NCT00322595 Phase 3 Quetiapine fumarate;Paroxetine
44 Treating Late-Life Generalized Anxiety Disorder (GAD) in Primary Care Completed NCT00308724 Phase 3
45 A Randomized Double-Blind, Placebo Controlled, Flexible Dose, Parallel Group Study of Extended-Release Lorazepam (EDG004) for the Treatment of Generalized Anxiety Disorder (GAD) Completed NCT02305797 Phase 3 Extended-release lorazepam;Placebo
46 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Pregabalin in Subjects With Generalized Anxiety Disorder (GAD) Switching From Benzodiazepine Therapy. Completed NCT00368745 Phase 3 Pregabalin;Placebo
47 A 10-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Flexible-Dosage Study to Evaluate the Efficacy and Safety of Gabitril (up to 16 mg/Day) in the Treatment of Adults With Generalized Anxiety Disorder Completed NCT00236054 Phase 3 Gabitril
48 A Multicenter, Randomized, Double-Blind, Placebo and Escitalopram Controlled Trial of the Safety and Efficacy of Pexacerfont (BMS-562086) in the Treatment of Outpatients With Generalized Anxiety Disorder Completed NCT00481325 Phase 2, Phase 3 pexacerfont;escitalopram;placebo
49 Long-Term Chamomile Therapy for Generalized Anxiety Disorder (GAD) Completed NCT01072344 Phase 3 Chamomile (Matricaria recutita)
50 A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Comparing the Efficacy and Safety of 2 Doses of Lu AA21004 in Acute Treatment of Adults With Generalized Anxiety Disorder Completed NCT00731120 Phase 3 Vortioxetine;Placebo

Search NIH Clinical Center for Generalized Anxiety Disorder

Genetic Tests for Generalized Anxiety Disorder

Anatomical Context for Generalized Anxiety Disorder

MalaCards organs/tissues related to Generalized Anxiety Disorder:

40
Amygdala, Cortex, Brain, Prefrontal Cortex, Heart, Skin, Eye

Publications for Generalized Anxiety Disorder

Articles related to Generalized Anxiety Disorder:

(show top 50) (show all 6805)
# Title Authors PMID Year
1
Duloxetine in the treatment of generalized anxiety disorder. 61 54
19337457 2008
2
Short-term tolerability of a nonazapirone selective serotonin 1A agonist in adults with generalized anxiety disorder: a 28-day, open-label study. 61 54
18840371 2008
3
Effects of PRX-00023, a novel, selective serotonin 1A receptor agonist on measures of anxiety and depression in generalized anxiety disorder: results of a double-blind, placebo-controlled trial. 54 61
18344738 2008
4
Azapirones for generalized anxiety disorder. 54 61
16856115 2006
5
An integrated in silico 3D model-driven discovery of a novel, potent, and selective amidosulfonamide 5-HT1A agonist (PRX-00023) for the treatment of anxiety and depression. 54 61
16722631 2006
6
Early response and 8-week treatment outcome in GAD. 54 61
16845651 2006
7
Serotonin transporter and tryptophan hydroxylase gene polymorphisms in Chinese patients with generalized anxiety disorder. 54 61
15722951 2005
8
SPECT imaging of serotonin transporter binding in patients with generalized anxiety disorder. 61 54
15538601 2004
9
Association studies of MAO-A, COMT, and 5-HTT genes polymorphisms in patients with anxiety disorders of the phobic spectrum. 61 54
15450911 2004
10
Occupancy of agonist drugs at the 5-HT1A receptor. 54 61
14985704 2004
11
Association of a MAOA gene variant with generalized anxiety disorder, but not with panic disorder or major depression. 54 61
12555227 2003
12
Serotonin, 5-hydroxyindoleacetic acid and serotonin transporter in blood peripheral lymphocytes of patients with generalized anxiety disorder. 61 54
12188031 2002
13
Serotonergic polymorphisms in patients suffering from alcoholism, anxiety disorders and narcolepsy. 54 61
11444684 2001
14
Inverse agonist binding of peripheral benzodiazepine receptors in anxiety disorder. 61 54
11697575 2001
15
Decreased platelet peripheral-type benzodiazepine receptors in adolescent inpatients with repeated suicide attempts. 54 61
10459397 1999
16
Benzodiazepine-induced chemotaxis is impaired in monocytes from patients with generalized anxiety disorder. 54 61
10101731 1999
17
Meta-analysis of the safety and tolerability of two dose regimens of buspirone in patients with persistent anxiety. 61 54
10356651 1999
18
Peripheral benzodiazepine receptor messenger RNA is decreased in lymphocytes of generalized anxiety disorder patients. 61 54
9606532 1998
19
Cerebral benzodiazepine receptor binding and distribution in generalized anxiety disorder: a fractal analysis. 61 54
9399689 1997
20
[The 5-HT1A receptor: a new effective principle in psychopharmacologic therapy?]. 61 54
9064274 1996
21
Altered platelet peripheral-type benzodiazepine receptor in posttraumatic stress disorder. 61 54
8866701 1996
22
A double-blind, placebo-controlled study of a CCK-B receptor antagonist, CI-988, in patients with generalized anxiety disorder. 61 54
8748432 1995
23
Efficacy trial of the 5-HT2 antagonist MDL 11,939 in patients with generalized anxiety disorder. 54 61
7714223 1995
24
The role of serotonin in depression and anxiety. 54 61
7622823 1995
25
Single-site findings in a study of the safety and efficacy of a CCKB receptor antagonist, CI-988, in the treatment of generalized anxiety disorder. 61 54
9160582 1994
26
Peripheral-type benzodiazepine receptors in anxiety disorders. 54 61
1686517 1991
27
COVID-19: anxiety among hospital staff and associated factors. 61
33350869 2021
28
Combination therapy with neuropeptides for the treatment of anxiety disorder. 61
33607407 2021
29
Clinical features associated with early drop-out among outpatients with unipolar and bipolar depression. 61
33127073 2021
30
Caregiver Speaks Study Protocol: A Technologically-Mediated Storytelling Intervention for Hospice Family Caregivers of Persons Living With Dementia. 61
32985230 2021
31
Associations between NT-proBNP and psychosocial factors in patients with chronic systolic heart failure. 61
33601116 2021
32
Effects of centralized isolation vs. home isolation on psychological distress in patients with COVID-19. 61
33581399 2021
33
Longitudinal associations between internalizing symptoms and driving avoidance in newly licensed adolescents. 61
33470424 2021
34
Protective effect of pregabalin on the brain tissue of diabetic rats. 61
33786275 2021
35
Intravenous ketamine for postmenopausal women with treatment-resistant depression: Results from the Canadian Rapid Treatment Center of Excellence. 61
32948309 2021
36
Effect of Tai Chi and Resistance Training on Cancer-Related Fatigue and Quality of Life in Middle-Aged and Elderly Cancer Patients. 61
33420583 2021
37
The Effect of a Psychotherapy Protocol on Dream Awareness in Adults With Generalized Anxiety Disorder. 61
33476107 2021
38
The proportion and associated factors of anxiety in Chinese adolescents with depression during the COVID-19 outbreak. 61
33592429 2021
39
Associations between feelings/behaviors during COVID-19 pandemic lockdown and depression/anxiety after lockdown in a sample of Chinese children and adolescents. 61
33592433 2021
40
Disruption of functional and structural networks in first-episode, drug-naïve adolescents with generalized anxiety disorder. 61
33618206 2021
41
A survey of anxiety and burnout in the radiology workforce of a tertiary hospital during the COVID-19 pandemic. 61
33591604 2021
42
Associations of saliva cortisol and hair cortisol with generalized anxiety, social anxiety, and major depressive disorder: An epidemiological cohort study in adolescents and young adults. 61
33592366 2021
43
Determinants of mental health outcomes among people with and without diabetes during the COVID-19 outbreak in the Arab Gulf Region. 61
33351239 2021
44
The association between anxiety disorders and hippocampal volume in older adults. 61
33661669 2021
45
Psychiatric Co-Morbidities in Post-Traumatic Stress Disorder: Detailed Findings from the Adult Psychiatric Morbidity Survey in the English Population. 61
32705407 2021
46
The association between anxiety and esophageal cancer: A nationwide population-based study. 61
33098157 2021
47
Lifetime Prevalence and Comorbidity of Mental Disorders in the Two-wave 2002-2018 Canadian Armed Forces Members and Veterans Mental Health Follow-up Survey (CAFVMHS): Prévalence et Comorbidité de Durée de vie Des Troubles Mentaux Dans l'Enquête de Suivi Sur la Santé Mentale Auprès des Membres des Forces Armées Canadiennes et Des ex-Militaires (ESSMFACM) en Deux Cycles de 2002 à 2018. 61
33715467 2021
48
Fatigue and its correlates in Indian patients with systemic lupus erythematosus. 61
33033858 2021
49
Impact of abuse on migraine-related sensory hypersensitivity symptoms: Results from the American Registry for Migraine Research. 61
33779989 2021
50
The impact of generalized anxiety disorder in obsessive-compulsive disorder patients. 61
33812219 2021

Variations for Generalized Anxiety Disorder

Expression for Generalized Anxiety Disorder

Search GEO for disease gene expression data for Generalized Anxiety Disorder.

Pathways for Generalized Anxiety Disorder

Pathways related to Generalized Anxiety Disorder according to GeneCards Suite gene sharing:

(show all 16)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.39 TSPO NR3C1 NPY NPSR1 HTR2A HTR1A
2 12.11 NPY HTR1A DRD2 BDNF
3 11.97 TPH1 SLC6A4 NR3C1 MAOA HTR3A HTR2A
4 11.86 TPH1 SLC6A4 MAOA HTR3A HTR2A HTR1A
5
Show member pathways
11.83 SLC6A3 MAOA DRD2 BDNF
6
Show member pathways
11.78 HTR2A HTR1A DRD2
7
Show member pathways
11.78 SLC6A4 SLC6A2 CYP2D6 COMT
8
Show member pathways
11.3 SLC6A4 SLC6A3 SLC6A2 MAOA
9
Show member pathways
11.04 SLC6A4 SLC6A3 MAOA COMT
10
Show member pathways
10.92 TPH1 MAOA COMT
11 10.88 TPH1 SLC6A4 MAOA HTR3A HTR2A HTR1A
12
Show member pathways
10.75 HTR3A CYP2D6
13
Show member pathways
10.71 MAOA COMT
14 10.67 MAOA COMT
15
Show member pathways
10.53 SLC6A4 SLC6A3 SLC6A2 MAOA HTR1A DRD2
16 10.45 MAOA CYP2D6

GO Terms for Generalized Anxiety Disorder

Cellular components related to Generalized Anxiety Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of membrane GO:0016021 10.27 TSPO SLC6A4 SLC6A3 SLC6A2 NPSR1 MAOA
2 integral component of plasma membrane GO:0005887 9.91 SLC6A4 SLC6A3 SLC6A2 NPSR1 HTR3A HTR2A
3 synapse GO:0045202 9.88 SLC6A4 NPY HTR3A HTR2A HTR1A DRD2
4 dendrite GO:0030425 9.83 HTR2A HTR1A DRD2 COMT BDNF
5 axon GO:0030424 9.8 SLC6A3 HTR3A HTR2A DRD2 COMT BDNF
6 neuron projection GO:0043005 9.7 TPH1 SLC6A4 SLC6A3 SLC6A2 RGS2 HTR3A
7 dopaminergic synapse GO:0098691 9.37 SLC6A3 DRD2
8 integral component of presynaptic membrane GO:0099056 9.35 SLC6A4 SLC6A3 HTR3A HTR2A DRD2
9 integral component of postsynaptic membrane GO:0099055 9.02 SLC6A4 SLC6A3 HTR3A HTR2A DRD2

Biological processes related to Generalized Anxiety Disorder according to GeneCards Suite gene sharing:

(show all 32)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.25 NR3C1 NPSR1 HTR3A HTR2A HTR1A DRD2
2 G protein-coupled receptor signaling pathway GO:0007186 10.12 RGS2 NPY NPSR1 HTR2A HTR1A DRD2
3 sodium ion transmembrane transport GO:0035725 9.82 SLC6A4 SLC6A3 SLC6A2
4 chemical synaptic transmission GO:0007268 9.8 SLC6A2 NPY HTR3A HTR2A HTR1A
5 memory GO:0007613 9.78 SLC6A4 HTR2A BDNF
6 response to ethanol GO:0045471 9.73 SLC6A3 RGS2 HTR3A DRD2
7 G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger GO:0007187 9.72 NPY HTR2A HTR1A
8 neurotransmitter transport GO:0006836 9.69 SLC6A4 SLC6A3 SLC6A2
9 response to iron ion GO:0010039 9.65 SLC6A3 DRD2
10 dopamine metabolic process GO:0042417 9.65 DRD2 COMT
11 response to cocaine GO:0042220 9.65 SLC6A3 HTR3A DRD2
12 behavior GO:0007610 9.64 HTR2A HTR1A
13 behavioral response to cocaine GO:0048148 9.63 HTR2A DRD2
14 neurotransmitter biosynthetic process GO:0042136 9.63 SLC6A4 SLC6A3
15 catecholamine metabolic process GO:0006584 9.62 MAOA COMT
16 prepulse inhibition GO:0060134 9.62 SLC6A3 DRD2
17 neurotransmitter catabolic process GO:0042135 9.61 MAOA COMT
18 negative regulation of voltage-gated calcium channel activity GO:1901386 9.6 DRD2 CRHR1
19 negative regulation of synaptic transmission, glutamatergic GO:0051967 9.59 HTR2A DRD2
20 regulation of dopamine metabolic process GO:0042053 9.58 SLC6A3 HTR1A
21 neurotransmitter reuptake GO:0098810 9.57 SLC6A4 SLC6A2
22 adenohypophysis development GO:0021984 9.56 SLC6A3 DRD2
23 hyaloid vascular plexus regression GO:1990384 9.54 SLC6A3 DRD2
24 response to pain GO:0048265 9.54 TSPO SLC6A2 COMT
25 norepinephrine uptake GO:0051620 9.52 SLC6A3 SLC6A2
26 vasoconstriction GO:0042310 9.5 SLC6A4 HTR1A CRP
27 dopamine uptake involved in synaptic transmission GO:0051583 9.49 SLC6A3 SLC6A2
28 norepinephrine transport GO:0015874 9.46 SLC6A3 SLC6A2
29 dopamine catabolic process GO:0042420 9.43 SLC6A3 MAOA COMT
30 monoamine transport GO:0015844 9.33 SLC6A4 SLC6A3 SLC6A2
31 response to drug GO:0042493 9.17 TSPO SLC6A4 SLC6A3 SLC6A2 HTR2A DRD2
32 serotonin receptor signaling pathway GO:0007210 9.13 HTR3A HTR2A HTR1A

Molecular functions related to Generalized Anxiety Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 G protein-coupled receptor activity GO:0004930 9.88 NPY NPSR1 HTR2A HTR1A DRD2 CRHR1
2 symporter activity GO:0015293 9.63 SLC6A4 SLC6A3 SLC6A2
3 neurotransmitter receptor activity GO:0030594 9.61 HTR3A HTR2A HTR1A
4 dopamine binding GO:0035240 9.37 SLC6A3 DRD2
5 neurotransmitter transporter activity GO:0005326 9.33 SLC6A4 SLC6A3 SLC6A2
6 dopamine:sodium symporter activity GO:0005330 9.32 SLC6A3 SLC6A2
7 norepinephrine:sodium symporter activity GO:0005334 9.26 SLC6A3 SLC6A2
8 monoamine transmembrane transporter activity GO:0008504 9.13 SLC6A4 SLC6A3 SLC6A2
9 serotonin binding GO:0051378 8.92 SLC6A4 HTR3A HTR2A HTR1A

Sources for Generalized Anxiety Disorder

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....